论文部分内容阅读
目的 :研究膀胱癌组织中 p16、p5 3及c erbB 2蛋白表达 ,探讨其与膀胱癌病理分级、临床分期和转移的关系。方法 :应用免疫组化SP法对 75例膀胱癌组织中p16、p5 3及c erbB 2蛋白表达进行检测。结果 :75例膀胱癌中 p16、p5 3及c erbB 2的阳性率分别为 41 3 % (31/ 75 )、44 % (33/ 75 )和 40 % (30 / 75 ) ,p16、和c erbB 2基因在膀胱癌中的阳性率与肿瘤病理分级和临床分期有显著性统计学意义 (P <0 .0 5 ) ,p5 3及c erbB 2阳性率与肿瘤临床分期及转移有密切的关系 (P <0 .0 1) .77.3% (5 8/ 75 )肿瘤有上述癌基因和 (或 )抑癌基因的异常表达 ,其中 5 3 .3 % (4 0 / 75 )的肿瘤同时有多个基因的表达异常。结论 :肿瘤的多基因分析比单基因分析更有价值 ,癌基因c erbB 2和抑癌基因p16、p5 3基因的表达异常及协同作用在膀胱癌的发生发展中起重要作用。
OBJECTIVE: To study the expression of p16, p5 3 and c erbB 2 in bladder cancer, and to explore their relationship with the pathological grade, clinical stage and metastasis of bladder cancer. Methods: The expressions of p16, p5 3 and c erbB 2 protein in 75 cases of bladder cancer were detected by immunohistochemical SP method. RESULTS: The positive rates of p16, p5 3 and c erbB 2 in 75 cases of bladder cancer were 41 3% (31/75), 44% (33/75), 40% (30/75), p16, and c erbB (P <0.05). The positive rates of p5 3 and c erbB 2 were closely related to the clinical stage and metastasis of tumor (P <0.05). The positive rates of p53 and c erbB 2 in bladder cancer were significantly correlated with the tumor pathological grade and clinical stage P <0.01) .Among the 77.3% (58/75) tumors, there were abnormal expression of the above oncogenes and / or tumor suppressor genes, of which 53.3% (40/75) had multiple Gene expression is abnormal. CONCLUSIONS: Multi-gene analysis of tumors is more valuable than single-gene analysis. Aberrant expression of the c erbB 2 and p16, p5 3 genes and their synergistic effects play an important role in the development of bladder cancer.